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Migraine and metabolic syndrome are highly prevalent and costly conditions.The two con-
ditions coexist, but it is unclear what relationship may exist between the two processes.
Metabolic syndrome involves a number of findings, including insulin resistance, systemic
hypertension, obesity, a proinflammatory state, and a prothrombotic state. Only one study
addresses migraine in metabolic syndrome, finding significant differences in the presen-
tation of metabolic syndrome in migraineurs. However, controversy exists regarding the
contribution of each individual risk factor to migraine pathogenesis and prevalence. It is
unclear what treatment implications, if any, exist as a result of the concomitant diagnosis
of migraine and metabolic syndrome.The cornerstone of migraine and metabolic syndrome
treatments is prevention, relying heavily on diet modification, sleep hygiene, medication
use, and exercise.
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INTRODUCTION
Migraine is a condition that is usually characterized by a mod-
erate or severe throbbing headache, unilateral pain, nausea or
vomiting, light and sound sensitivity, and disability. Neurologic,
gastrointestinal (Aurora et al., 2007), and autonomic symptoms
(Blau, 1992) may be present. Experts believe that some indi-
viduals have a genetic predisposition for migraine (Van Den
Maagdenberg et al., 2010) and defective pain control mecha-
nisms (Aderjan et al., 2010). Vascular dilation and inflamma-
tion (Viola et al., 2010) occur in acute migraine, but migraine
is now felt to be a neuronal disorder (Ba’albaki and Rapoport,
2008). Migraine pathogenesis involves the release of inflam-
matory neuropeptides [such as calcitonin gene-related peptide
(CGRP)], trigeminal activation (Buzzi and Tassorelli, 2010), and
cortical spreading depression (Milner, 1958; Ayata, 2010; Viola
et al., 2010). Migraine is associated with many comorbid cen-
tral and peripheral disorders, such as ischemic stroke, Raynaud
phenomenon, epilepsy, depression, anxiety, obesity, and possibly
metabolic syndrome (Guldiken et al., 2009; Buse et al., 2010).
The interplay and causality of migraine and its comorbid dis-
orders is not well understood (Marmura, 2009), particularly
in regard to migraine’s association with obesity and metabolic
syndrome.
Metabolic syndrome includes a number of abnormalities,
including hypertension, insulin resistance, atherogenic dyslipi-
demia, a proinflammatory state, a prothrombotic state, and
increased waist circumference or obesity (Alberti et al., 2006). Sev-
eral organizations have proposed diagnostic criteria for metabolic
syndrome (Alberti et al., 2006), contributing to confusion con-
cerning the most useful definition in any given patient population.
Some have questioned if diagnosing metabolic syndrome is use-
ful to patient care (Kahn et al., 2005; Anscombe et al., 2006). The
presence of metabolic syndrome has been associated with a signif-
icant risk of cardiovascular disease (Mottillo et al., 2010), stroke
(Gupta et al., 2010), and type 2 diabetes (Aschner, 2010). Obesity
may also be a risk factor for migraine, especially chronic migraine.
METABOLIC SYNDROME, INSULIN RESISTANCE, AND
MIGRAINE
Although studies of metabolic syndrome components (hyperten-
sion, hyperlipidemia, insulin resistance, adiposity) and migraine
exist, only one study characterized metabolic syndrome patients
with migraine. Guldiken et al. (2009) surveyed 210 patients who
met Adult Treatment Panel 3 (ATP III) criteria for metabolic syn-
drome. They assessed headache symptoms lasting more than a year
and meeting International Classification of Headache Disorders-
II (ICHD-II) criteria for migraine. Patients with migraine and
metabolic syndrome (n= 41, 19.5%) were significantly more likely
to have diabetes, increased waist circumference, and elevated
body-mass index than patients with metabolic syndrome with-
out migraine. These findings indicate that insulin resistance may
be associated with migraine pathogenesis. Several lines of evi-
dence support this theory. Studies of migraine triggers indicate
that 46.3% (Yadav et al., 2010) – 57.3% (Hauge et al., 2010) of
migraineurs associate fasting with migraine onset. Additionally,
two clinic-based population studies of ICHD-II–defined adult
migraineurs found that insulin resistance is significantly altered
in (1) young, non-obese, non-diabetic, normotensive migraine
patients as opposed to healthy control subjects (Rainero et al.,
2005), and (2) migraine patients compared with non-migraine
headache patients (Cavestro et al., 2007). One group reported
a link between insulin receptor gene polymorphism at locus
19p13.3/2 and migraine with aura (McCarthy et al., 2001; Kaunisto
et al., 2005; Curtain, 2006; Netzer et al., 2008), although it is unclear
if this polymorphism confers a loss or gain of function. While
insulin receptors are found in many regions of the brain, the signals
that these receptors propagate and the effect of resistance on their
activity remains unclear. The clinical characteristics of migraine
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itself may lead to metabolic syndrome. Physical activity usually
worsens migraine symptoms during acute attacks, which could
lead patients to avoid exercise (ICHD-2 criteria for migraine).
Affective disorders or medications used to treat migraine, such as
antidepressants, commonly cause weight gain (Young and Rozen,
2005; Table 1). Even topiramate, which tends to decrease weight,
may worsen or cause dyslipidemia (Franzoni et al., 2007).
SYSTEMIC BLOOD PRESSURE AND MIGRAINE
A few studies have reported the presence of blood pressure abnor-
malities (systolic or diastolic) in migraine. Hypertension is clearly
linked to cerebrovascular disease (Netzer et al., 2008) and has been
associated with self-reported headache (subtype unspecified; Cir-
illo et al., 1999). Severe headache is a common symptom of a
hypertensive emergency. Blood pressure abnormalities have been
associated with migraine in pregnancy (Adeney and Williams,
2006), migraine with aura, and chronic migraine (Granella et al.,
1987). Migraine is a risk factor for pre-eclampsia and gesta-
tional hypertension (Allais et al., 2010). Studies of hypertension
in non-pregnant adults with migraine are conflicting. A large
demographic study positively associated migraine with systolic
hypertension (Buse et al., 2010). However, other studies have asso-
ciated systolic hypertension with chronic daily headache (Gipponi
et al., 2010) and chronic migraine (Bigal et al., 2002; Barbanti
et al., 2010), but not episodic migraine or tension-type headache
in non-pregnant adult patients. Diastolic hypertension has been
associated with increased frequency of episodic migraine in one
study (Gudmundsson et al., 2006) but diastolic hypotension was
non-significantly associated with migraine in another study (Seçil
et al., 2010). Some have suggested that autonomic dysfunction is an
important part of migraine; many migraineurs exhibit symptoms,
such as diarrhea or sweating, of parasympathetic over-activity
(Melek et al., 2007). Further study will be required to assess the
role of blood pressure abnormalities in migraine.
MIGRAINE AND OBESITY
Obesity is a major public health problem (Friedman, 2009).
Obesity has been associated with numerous pain syndromes,
Table 1 | Select migraine prophylactic medications and accompanying
metabolic effects.
Migraine type Metabolic
derangement
Reference
Migraine NOS Increased insulin
resistance
Rainero et al. (2005)
Migraine NOS Increased systolic blood
pressure
Buse et al. (2010)
Migraine NOS Increased serum IL-6 Recober and Goadsby
(2010)
Chronic migraine Increased systolic blood
pressure
Barbanti et al. (2010)/
Bigal (2010)
Episodic migraine Decreased serum leptin Guldiken et al. (2008)
Menstrual
migraine
Increased serum
TNF-alpha
Mueller et al. (2001)
Chronic daily
headache
Increased systolic blood
pressure
Gipponi et al. (2010)
including chronic pain (Ray et al., 2010), fibromyalgia (Okifuji
et al., 2010), low back pain (Heuch et al., 2010), and neck pain
(Mäntyselkä et al., 2010). Migraine patients may have multiple
metabolic abnormalities associated with obesity, including cere-
brospinal fluid (CSF) neuropeptide Y elevation (Valenzuela et al.,
2000), CSF tumor necrosis factor alpha (TNF) elevation (Rozen
and Swidan, 2007), and systemic adiponectin depression (Peterlin
et al., 2007). Given the recently characterized metabolic activity of
adipose tissue (Bigal et al., 2007a), the interaction between obesity
and migraine is particularly complex and has been the subject of
multiple large and conflicting studies.
Population-based studies suggest that obesity is not associ-
ated with migraine prevalence (Bigal et al., 2006b) but may
be a risk factor for the transformation of episodic migraine to
chronic migraine (Scher et al., 2003; Bigal and Lipton, 2006).
Bigal et al. studied 30,215 subjects, 3,791 of whom reported
migraine symptoms. In age-, education-, and race-adjusted mod-
els, migraine prevalence was not significantly associated with ele-
vated body-mass index (BMI). However, increasing weight was
associated with increasing headache frequency, severity, and dis-
ability (Bigal et al., 2006a). Bigal et al. (2007b) further identified
18,968 migraine patients from a validated, mailed survey and
compared them to patients with probable migraine and severe
episodic tension-type headache. Bigal et al. (2007b) found that
BMI and headache frequency and disability were positively cor-
related in the migraine patient population but not in other
headache groups. Winter et al. (2009) confirmed these findings
in a survey of 63,467 women age >45 years, wherein they found
that women with a high BMI (morbid obesity) and current (as
opposed to historical) migraine attacks were more likely to suf-
fer from more frequent migraine (OR 3.11 for daily migraine
vs. lower BMI groups) and migraines with phonophobia and
photophobia but not with aura. Finally, Tietjen et al. (2007)
studied 721 migraine patients recruited from eight study cen-
ters and found that patients with migraine, obesity, depression,
and anxiety had greater migraine frequency and migraine-related
disability.
Several studies failed to find any association between migraine
and obesity. Keith et al. (2008) surveyed 11 independent datasets
totaling 220,370 females with headache, reporting no association
between diagnosed migraine and BMI. Molarius et al. (2008)
found no association between obesity and self-reported migraine
in a survey of 43,770 patients. Mattsson (2007) studied 684 females
age 40–74 and did not find any association between obesity
and migraine prevalence, frequency, severity, or disability. Tellez-
Zenteno et al. (2010) surveyed 1,371 migraine patients and 612
age- and gender-matched controls. They found that migraine
patients were more likely to be overweight but less likely to be
obese or morbidly obese (Tellez-Zenteno et al., 2010). They addi-
tionally did not find any association between weight and headache
severity or frequency (Tellez-Zenteno et al., 2010). Unfortunately,
many patients with migraine are unaware of their diagnosis, often
labeling frequent headaches as “sinus” or “stress” headaches (Eross
et al., 2007).
A number of smaller studies found an association between BMI
and migraine prevalence. Peterlin et al. (2010) proposed that dif-
ferences in visceral as opposed to subcutaneous adipose tissue
may help explain sex differences in migraine prevalence. Women
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after menopause and men both tend to have more abdominal
obesity stored in visceral tissue, placing them at increased risk for
hypertension, hyperlipidemia, and cardiovascular events. Subcu-
taneous fat, often in the gluteo-femoral region in women, appears
to increase leptin and adiponectin levels, which may impair insulin
sensitivity and modulation of inflammatory processes contribut-
ing to migraine risk. In a 7,601 patient sub-population of the
National Health and Nutrition Examination Survey, Ford et al.
(2008) reported that overweight and underweight patients were
more likely to suffer from migraine. Horev et al. (2005) interviewed
27 morbidly obese women patients, reporting migraine symptoms
in 13 patients (10 with aura) and tension-type headache in an
additional 4 patients. In the adolescent population, Pinhas-Hamiel
et al. (2008) surveyed 273 individuals and uncovered 39 children
with headache and 15 with migraine. Increasing weight was asso-
ciated with increased headache prevalence (Pinhas-Hamiel et al.,
2008). Of note, migraine patients tend to significantly underesti-
mate self-reported weight and BMI when compared with actual
measurements (Katsnelson et al., 2009).
THE METABOLIC ACTIVITY OF EXCESS ADIPOSE TISSUE LIKELY
CONTRIBUTES TO A PROINFLAMMATORY STATE, CONTRIBUTING TO
MIGRAINE PATHOGENESIS
While the relationship between migraine and obesity is contro-
versial, most large studies suggest that obesity is not associated
with migraine prevalence, but may be associated with increased
headache frequency.
Multiple neurotransmitters and hormones, including CGRP,
substance P, neuropeptide Y (Valenzuela et al., 2000), adiponectin
(Peterlin et al., 2007), leptin (Guldiken et al., 2008), orexin-A (Ray
and Kumar, 2010), interleukin (IL)-1 (Yilmaz et al., 2010), IL-6,
and TNF-α have been implicated in migraine pathogenesis (Rozen
and Swidan, 2007; Yilmaz et al., 2010). Adipocytes and associ-
ated macrophages are known to be metabolically active (Bigal
et al., 2007a), producing many mediators of migraine. Adiponectin
and leptin, hormones involved in the regulation of appetite and
metabolism, play a central role in adipose tissue development and
subsequent aberrations in the metabolic milieu of obesity (Arita
et al., 1999; Stofkova, 2009). Serum adiponectin levels have been
inversely correlated with BMI (Arita et al., 1999) and adiponectin
may mediate many of the inflammatory metabolites associated
with migraine (Peterlin et al., 2007). Leptin is an adipose-derived
hormone that helps regulate appetite and metabolism, produced
by adipose tissue and increased in obese patients. Leptin acts on
receptors in the hypothalamus combating the effect of feeding
stimulants, such as neuropeptide Y, reducing appetite (Peterlin,
2009). Elevated serum leptin is also known to enhance both innate
and adaptive immune system activity (Stofkova, 2009). In one
study of episodic migraine subjects, Leptin was decreased com-
pared to controls with similar BMI (Guldiken et al., 2008), but the
duration of disease may be an overlooked factor. In patients with
acute inflammation, levels are increased, but they decrease with
chronic exposure to inflammation, suggesting that patients with
a long history or frequent migraine would be at greatest risk of
weight gain (Peterlin, 2009).
Vascular dilation and inflammation are thought to contribute
to migraine pathogenesis and pain symptoms. Inflammatory and
immune mediators, including TNF-α, IL-1, CGRP, orexin, and IL-
6, are involved in migraine pathogenesis, and substance P, CGRP,
and IL-6 are elevated during acute migraine attacks (Jang et al.,
2010). TNF-α is a proinflammatory molecule produced by excess
adipose tissue (Rönnemaa et al., 2000) and serum TNF-α levels
are elevated in menstrual migraine (Mueller et al., 2001). The gain
of function TNF-α-308 A and IL-1β+ 3953 T allele gene poly-
morphisms are elevated in patients with migraine without aura
(Yilmaz et al., 2010), although the implications are unclear. CGRP
is a neurotransmitter that mediates nociceptive transmission from
the trigeminal nerve complex to the thalamus (Summ et al., 2010).
Elevated CGRP levels have been detected in obese patients, confer-
ring further risk of migraine in susceptible patients (Recober and
Goadsby, 2010). Similarly, IL-6 is elevated in migraine patients
regardless of current treatment protocol and is thought to lower
the pain thresholds. Orexin-A and B receptors have been studied in
migraine. Orexin-A is thought to depress CGRP release (Holland
et al., 2005), and orexin activation is thought to confer resistance
to dietary related features of metabolic syndrome (Funato et al.,
2009). Migraine and obesity independently give rise to an altered
inflammatory and immune marker milieu, and further research
will be required to elucidate how these two diseases interact.
IT IS UNCLEAR IF OBESITY CAUSES MIGRAINE OR IF MIGRAINE
CAUSES OBESITY
Obesity, like other comorbid states in migraine, is a result of
genetic and environmental susceptibility to disease. It is unclear
if migraine, or its treatment, is a cause of obesity, or if obesity
causes increased migraine frequency. Exercise increases endorphin
levels and pain tolerance and in rats decreases opioid usage (Hos-
seini et al., 2009) and increases insulin sensitivity (Su et al., 2005).
Physical activity tends to exacerbate symptoms of migraine, so it is
likely that patients with frequent migraine would avoid strenuous
activity. In most studies, obesity does not predispose to increased
migraine prevalence, but it could be a risk factor for more frequent
or severe attacks.
MIGRAINE AND PROTHROMBOTIC STATE
Metabolic syndrome is associated with an acquired prothrombotic
state. Thrombosis is a leading cause of multiple cardiovascular and
cerebrovascular disease processes. Migraine, particularly migraine
with aura, is associated with an increased risk of cardiovascu-
lar and cerebrovascular disease in epidemiological studies (Kurth
et al., 2006; Allais et al., 2008); however, objective ultrasound-based
measures of atherosclerosis do not support a greater atheroscle-
rotic burden in migraineurs when compared with headache-free
controls (Moschiano et al., 2007). Migraine without aura is not
associated with an increased burden of vascular disease (Kurth
et al., 2006). Certain migraine syndromes, particularly in migraine
with aura, are associated with computed tomography and mag-
netic resonance imagining findings, including infarct-like white
matter changes (Moschiano et al., 2007). These infarcts may accu-
mulate over time as seen on follow-up studies (Kruit et al., 2010).
The cause of these findings are unclear, but seem to correlate
with attack frequency. One possibility is that spreading oligemia
during migraine aura may lead to subclinical ischemia. There
is no evidence to support anticoagulation in migraine and it is
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unclear whether an acquired prothrombotic state would increase
the prevalence of migraine.
Gain of function platelet glycoprotein polymorphisms have
been associated with a minor increase in risk of migraine; however,
these polymorphisms have been more strongly associated with
multiple neurologic phenomena and a putative mechanism for
the association with migraine requires further study (Herak et al.,
2009). In the pediatric migraine population, factor V Leiden, fac-
tor II G20210A, methylenetetrahydrofolate reductase (MTHFR)
C677T, and A1298C mutation frequency are not significantly
associated with migraine; however elevated homocysteine and
depressed folate levels may be (Bottini et al., 2006). Except in cases
with antiphospholipid antibody syndrome (Asherson et al., 2007)
and patient foramen ovale (PFO; Wilmshurst et al., 2005), anti-
coagulation or antithrombotic agents do not appear to prevent
migraine.
Adult and pediatric patients with migraine with aura are sig-
nificantly more likely to have PFO than those in the general popu-
lation. PFO-associated microembolization of cortical vasculature
may contribute to the initiation of cortical spreading depression
in migraine with aura (Rigatelli et al., 2010). An observational,
prospective study reports that 89% of migraine patients with PFO
improved following closure, with 46% reporting cure at 12 months
(Trabattoni et al., 2011). However, a randomized, double-blind,
sham-controlled trial did not find a significant association from
PFO closure and improved migraine symptoms (Dowson et al.,
2008).
CLINICAL IMPLICATIONS
Migraine treatment may be acute or preventive, and patients
with severe, frequent attacks may require both. Because patients
with chronic migraine have frequent or even daily headaches,
preventive treatments are key, and preventive treatments, such
as weight loss and behavior modification, are critical to avoid-
ing the development of metabolic syndrome and managing and
avoiding the cardiovascular implications of the disease (Bond
et al., 2010). However, significant controversy exists regarding
the relationship between metabolic syndrome and migraine and
the effect that treating one has on abating the other. Further, the
subcomponents of metabolic syndrome, including insulin resis-
tance, elevated blood pressure, obesity, proinflammatory state, and
prothrombotic state, have an unclear association with migraine
prevalence, frequency, and characteristics (Table 2). It is unknown
if treating metabolic syndrome risk factors results in a decrease
in migraine attack rates or duration, or susceptibility to migraine
development. Finally, the prevalence of metabolic syndrome in the
migraine population has not been assessed.
MIGRAINE DIETS, FOOD AVOIDANCE, AND SUPPLEMENTS MAY BE
USEFUL IN MIGRAINE, BUT THESE TREATMENTS ARE NOT SPECIFIC TO
MIGRAINEURS WITH METABOLIC SYNDROME
While food related headache triggers are well documented (Alpay
et al., 2010) the use of so-called “migraine diets,” designed to
minimize migraine frequency and food sensitization, has been
controversial (Damen et al., 2006). One small trial of 30 patients
with migraine without aura does support food avoidance based on
detection of circulating serum immunoglobulins against specific
foods; however, larger studies are required to determine the effi-
cacy of this technique (Alpay et al., 2010). Four non-prescription
supplements, including magnesium, Petasites hybridus, coenzyme
Q10, and riboflavin, have been found to be effective migraine
preventive agents based on double-blind placebo-controlled trials
(Sun-Edelstein and Mauskop, 2009). However, supplementation
is not intended exclusively for the obese population.
SLEEP DISTURBANCE IS ASSOCIATED WITH INCREASED HEADACHE
SEVERITY BUT NOT SPECIFICALLY MIGRAINE IN PATIENTS WITH
METABOLIC SYNDROME
Obesity can cause sleep abnormalities (Kopelman, 2000), which
may worsen headaches and general health (Rains, 2008). In partic-
ular, obstructive sleep apnea and sleep disturbance are associated
with chronic migraine and chronic daily headache (Rains and
Poceta, 2006). Obstructive sleep apnea is also associated with
metabolic syndrome (Bhushan et al., 2010). Weight loss is fre-
quently curative in obese patients with obstructive sleep apnea.
In patients who do not lose weight, continuous positive airway
pressure therapy appears to reduce apnea-associated headache fre-
quency (Rains and Poceta, 2010). Further, good sleep hygiene may
reduce migraine frequency (Gilman et al., 2007).
MEDICATION CHOICE IN MIGRAINE PREVENTION MAY HAVE
IMPLICATIONS FOR WEIGHT GAIN AND CONCOMITANT METABOLIC
SYNDROME MANAGEMENT
Numerous medications used in the treatment of migraine,
including tricyclic antidepressants (i.e., amitriptyline; Taylor,
Table 2 | Select metabolic derangements found in migraine by migraine type.
Drug class Medication Metabolic effect Reference
Antiepileptic Topiramate Weight loss, dyslipidemia Franzoni et al. (2007)
Tricyclic antidepressant Amitriptyline Reduction in serum orexin-A and orexin-B levels.
Increase in serum neuropeptide Y. Weight gain.
Increased serum leptin, C-peptide, and insulin insulin
Caproni et al. (2011),
Berilgen et al. (2005)
Beta-adrenergic receptor blocker Propranolol Weight gain, worsening of glycemic and lipidic control
(non-vasodilating beta-blockers as a drug class)
Sharma et al. (2001),
Fonseca (2010)
SSRI/SNRI Venlafaxine Weight gain, hypertension at high dose Harrison et al. (2004)
Antiepileptic Valproic acid and derivatives Increased BMI, serum insulin, leptin, neuropeptide Y Tokgoz et al. (2012),
Pylvänen et al. (2002)
NOS=Not otherwise specified.
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2008), beta-adrenergic blockers (i.e., propranolol; Taylor, 2008),
antiepileptic drugs (e.g., divalproex sodium and gabapentin; Tay-
lor, 2008), and selective serotonin and norepinephrine reup-
take inhibitors, cause weight gain (Young, 2008). Although their
headaches improve with preventive migraine treatment (Bigal
et al., 2006a), fear of gaining weight is the most common
reason patients stop taking their migraine preventive medica-
tion (Kowacs et al., 2009). Weight gain from migraine therapy
is associated with a significant increase in the cardiovascular
risk factors associated with metabolic syndrome (Bigal et al.,
2009).
Topiramate is a popular preventive migraine treatment (Kowacs
et al., 2009). Topiramate monotherapy is at least as effective as
amitriptyline monotherapy in preventing headaches and improv-
ing functionality (Dodick et al., 2009), and it is hypothesized to
cause centrally mediated weight loss (Schütt et al., 2010). Topira-
mate has been suggested as a single-agent short-term adjuvant
to exercise and caloric restriction regimens for weight loss in
the non-headache population (Bays, 2010). This indication is
off-label and requires further study; particularly because a high
BMI at baseline is not predictive of which migraine patients
will lose weight on topiramate (Alberici et al., 2009). Topiramate
monotherapy in migraine has been associated with significant
elevations of serum uric acid, increasing risk of nephrolithia-
sis, and non-significant serum triglyceride elevation (Koçer et al.,
2008).
OnabotulinumtoxinA (BTX) is also effective in migraine pro-
phylaxis, particularly chronic migraine (Aurora et al., 2010). BTX
is potentially very useful in patients whose compliance is poor or in
whom other medications are contraindicated. BTX does not cause
weight gain and systemic adverse events are rare (Gobel, 2004).
Migraine and concomitant depression is a well described phe-
nomenon, and in many cases depression is secondary to the
migraine patient’s decreased quality of life. However, recent work
appears to suggest that depression itself may confer a significant
risk of migraine and that serotonin may mediate both processes
(Marino et al., 2010). Despite the potential interrelated patho-
physiology of migraine and depression, and the utility of tricyclic
antidepressants in migraine prophylaxis, the efficacy of the SSRI
class of medications in migraine prevention has been questioned
(Moja et al., 2005). One case report suggested that SSRIs may
worsen acute migraine attacks (Bickel et al., 2005). SSRIs and
SNRIs are known to cause weight gain (Young, 2008). However,
these classes of medications may provide adequate migraine pro-
phylaxis for patients who cannot tolerate tricyclic antidepressants
and have concomitant (or primary) depression. Patients with
depression have higher rates of metabolic syndrome than non-
depressed control subjects (East et al., 2010). It is not known
whether depression or medication-related weight gain confers a
greater risk of developing metabolic syndrome; however, treat-
ing depression is known to improve quality of life (Culpepper,
2010).
PHYSICAL ACTIVITY IS EFFECTIVE IN REDUCING RISK OF METABOLIC
SYNDROME AND INACTIVITY MAY BE ASSOCIATED WITH MIGRAINE
Several large population studies suggest that reduced physical
activity is associated with migraine. Milde-Busch et al. (2010)
surveyed 1,260 10th and 11th grade adolescents for ICHD-II–
criteria migraine and tension-type headache and found a 3.4×
risk of self-reported migraine symptoms in subjects with physical
inactivity. In the HUNT study, Robberstad et al. (2010) reported
that, among a subset of 5,847 adolescents assessed for recurrent
headache symptoms (migraine or tension-type), physical activity,
smoking status, and weight, overweight subjects were 1.4× more
likely to report recurrent headache and those with low physical
activity were 1.2× more likely to report recurrent headache. In
a broader cross sectional survey of 46,648 individuals, also per-
formed by the HUNT study group, low physical activity (sweating
or exercising during leisure time to the point of being out of breath
less than 1 h per week) was associated with a higher incidence of
self-reported migraine and non-migraine headache (Varkey et al.,
2008). A single patient case report suggests that intense running
may abort an evolving migraine, though this has yet to be repro-
duced (Strelniker, 2009). Similarly, a high level of physical activity
may confer a reduced risk of metabolic syndrome (Dai et al.,
2010).
Several studies have evaluated aerobic exercise programs in
migraine patients (Köseoglu et al., 2003; Dittrich et al., 2008;
Varkey et al., 2009). These programs have focused on increas-
ing oxygen uptake and have been well tolerated except for rare
post-exercise migraines (Varkey et al., 2009). Aerobic programs
have demonstrated improved depression (Dittrich et al., 2008) and
pain severity (Lockett and Campbell, 1992) scores. It is hypothe-
sized that aerobic exercise programs are associated with basal beta
endorphin levels, potentially modifying pain sensation threshold
(Köseoglu et al., 2003). For patients with metabolic syndrome,
exercise is more complicated. Studies reviewing exercise protocols
for obese patients and in rats indicate that a mix of resistance
and endurance training may be indicated to improve cardiovas-
cular disease risk endpoints (Hansen et al., 2010; Touati et al.,
2010).
CONCLUSION
Metabolic syndrome and migraine are highly complex biochem-
ical processes. It is likely that the two interact; however, it is
unclear how they do. Further research will be required to elu-
cidate the best clinical practices in patients who present with
both diseases. Weight loss, good sleep hygiene, increased physi-
cal activity, and management of life stressors are the cornerstone
of preventive healthcare in the adult population. These should be
encouraged in all patients, although the exact benefits in patients
with migraine and metabolic syndrome are unclear. Preventive
treatments, including nutraceuticals, pharmaceuticals, and avoid-
ance of triggers, are commonly accepted migraine treatments. The
choice of pharmaceutical may have implications for the manage-
ment of metabolic syndrome; however, much has yet to be learned
about the long-term use of all preventive medications. Consul-
tation with the patient regarding pharmacologic side effects is
necessary.
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